Andrew Wilson
Last active: 3/3/2020


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D (2018) Gynecol Oncol 149(3): 575-584
    › Primary publication · 29567272 (PubMed) · PMC5986599 (PubMed Central)
  2. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. Beeghly-Fadiel A, Wilson AJ, Keene S, El Ramahi M, Xu S, Marnett LJ, Fadare O, Crispens MA, Khabele D (2018) J Ovarian Res 11(1): 17
    › Primary publication · 29482584 (PubMed) · PMC5828488 (PubMed Central)
  3. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D (2016) Gynecol Oncol 143(1): 143-151
    › Primary publication · 27444036 (PubMed) · PMC5031537 (PubMed Central)
  4. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D (2015) Oncotarget 6(25): 21353-68
    › Primary publication · 25972361 (PubMed) · PMC4673270 (PubMed Central)
  5. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D (2014) Gynecol Oncol 133(3): 599-606
    › Primary publication · 24631446 (PubMed) · PMC4347923 (PubMed Central)
  6. TR3 modulates platinum resistance in ovarian cancer. Wilson AJ, Liu AY, Roland J, Adebayo OB, Fletcher SA, Slaughter JC, Saskowski J, Crispens MA, Jones HW, James S, Fadare O, Khabele D (2013) Cancer Res 73(15): 4758-69
    › Primary publication · 23720056 (PubMed) · PMC3944084 (PubMed Central)
  7. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D (2012) Gynecol Oncol 127(3): 579-86
    › Primary publication · 23010348 (PubMed) · PMC3541411 (PubMed Central)
  8. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. Wilson AJ, Cheng YQ, Khabele D (2012) J Ovarian Res 5(1): 12
    › Primary publication · 22531354 (PubMed) · PMC3394212 (PubMed Central)
  9. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA (2012) Int J Clin Exp Pathol 5(1): 37-45
    › Primary publication · 22295145 (PubMed) · PMC3267484 (PubMed Central)